None
Quote | AnaptysBio Inc. (NASDAQ:ANAB)
Last: | $20.23 |
---|---|
Change Percent: | 7.21% |
Open: | $18.92 |
Close: | $18.87 |
High: | $20.24 |
Low: | $18.715 |
Volume: | 181,852 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
News | AnaptysBio Inc. (NASDAQ:ANAB)
Actym Therapeutics Appoints Thomas Smart as CEO PR Newswire BERKELEY, Calif. , April 24, 2024 /PRNewswire/ -- Actym Therapeutics , pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Off...
2024-04-16 09:00:05 ET David Risinger from Leerink Partners issued a price target of $47.00 for ANAB on 2024-04-16 07:27:00. The adjusted price target was set to $47.00. At the time of the announcement, ANAB was trading at $21.27. The overall price target consensus is at...
Message Board Posts | AnaptysBio Inc. (NASDAQ:ANAB)
Subject | By | Source | When |
---|---|---|---|
HighPeaks, The NY Times article was | gfp927z | investorshub | 06/10/2022 4:40:20 PM |
Thanks TP. Yeah this has the potential to | HighPeaks | investorshub | 06/10/2022 3:36:11 PM |
Tremendous find HighPeaks. .You have been early on | tedpeele | investorshub | 06/10/2022 5:30:31 AM |
According to this link ANAB gets 8-25% royalties | HighPeaks | investorshub | 06/08/2022 7:33:46 PM |
$ANAB / #Anaptysbio Spikes After Drug Designation | TFMG | investorshub | 07/09/2020 1:28:42 AM |
News, Short Squeeze, Breakout and More Instantly...
Actym Therapeutics Appoints Thomas Smart as CEO PR Newswire BERKELEY, Calif. , April 24, 2024 /PRNewswire/ -- Actym Therapeutics , pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Off...
2024-04-16 09:00:05 ET David Risinger from Leerink Partners issued a price target of $47.00 for ANAB on 2024-04-16 07:27:00. The adjusted price target was set to $47.00. At the time of the announcement, ANAB was trading at $21.27. The overall price target consensus is at...
2024-04-12 19:00:50 ET Many stocks were wobbly over the past few trading days, but we can't say that about biotech AnaptysBio (NASDAQ: ANAB) . The company's shares closed the week almost 8% higher in price, according to data compiled by S&P Global Market Intelligence , large...